

Antibiotics for uncomplicated lower respiratory tract infection in older adults

Submission date 29/08/2024	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 17/10/2024	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 23/06/2025	Condition category Respiratory	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

AFLOAT is a two-arm, double-blinded non-inferiority trial at multiple primary care sites. Non-complicated lower respiratory tract infections (LRTIs) are the most common reason for antibiotic prescription in the UK, despite most infections being viral in origin, to which antibiotics confer no meaningful results. Older people, aged 75+ are prescribed more antibiotics than any other age group in the UK. LRTI was estimated to cost the NHS ≈£190 million in 2005. Older people are at increased risk of a prolonged and more severe illness, development of pneumonia and exacerbation of pre-existing chronic conditions. Whether older patients with risk factors for complications benefit from antibiotics is unknown and NICE guidance recommends considering immediate or delayed antibiotics for this group when presenting with non-complicated LRTIs. This leaves prescribing clinicians with frequent dilemmas over whether to prescribe antibiotics in this patient population. Antibiotic overuse can increase the risk of carriage of antibiotic-resistant organisms, which is a threat both for the individual treated and wider society. Antibiotic prescriptions also lead to the medicalisation of self-limiting illness and double re-consultation rates. However, under-prescription of antibiotics may put older people at increased risk of prolonged and more severe illness and pneumonia. This study will look at whether a placebo is non-inferior to antibiotics. The study assesses whether the duration of illness (time until all symptoms are rated absent or mild) is no worse in those who take placebo versus antibiotics in adults aged 65 years old and over who are seen in primary care with LRTI and risk factors for complications.

Who can participate?

Adult patients aged 65 years old and over with symptoms of uncomplicated LRTI and 1 or more risk factors for complications (aged > 80 years, recent hospital admission, chronic conditions, frailty).

What does the study involve?

Participants will be randomised into the doxycycline arm or matched placebo arm and asked to complete a daily diary for a 28-day follow-up period.

What are the possible benefits and risks of participating?

Benefits not given at time of publication.

There is a risk of potentially worsening of LRTI. As detailed above, patients will be given safety netting information for when to contact their healthcare providers.

Where is the study run from?

University Hospital Southampton, UK

When is the study starting and how long is it expected to run for?

August 2024 to July 2027

Who is funding the study?

NIHR Health Technology Assessment Programme (HTA)

Who is the main contact?

afloat@soton.ac.uk

Contact information

Type(s)

Scientific

Contact name

Mrs Alice O'Neill

Contact details

Trial Manager, Southampton Clinical Trials Unit (SCTU), Mail point 131, University Hospital

Southampton, Tremona Road

Southampton

United Kingdom

SO16 6YD

+44 (0)23 8120 5154

a.r.leaper@soton.ac.uk

Type(s)

Principal Investigator

Contact name

Dr Mark Lown

Contact details

Aldermoor Surgery, Aldermoor Close

Southampton

United Kingdom

SO16 5ST

-

M.Lown@soton.ac.uk

Type(s)

Public

Contact name

Dr Study Team

Contact details

Central email for Southampton Clinical Trials Unit (SCTU), Mail point 131, University Hospital
Southampton, Tremona Road

Southampton

United Kingdom

SO16 6YD

-

afloat@soton.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

1010353

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

ERGO77292, CPMS 56324, NIHR157478

Study information

Scientific Title

Antibiotics for uncomplicated Lower respiratory tract infection in Older Adults

Acronym

AFLOAT

Study objectives

Primary objective:

To test whether placebo is non-inferior to antibiotics in terms of time until all symptoms are rated mild or absent in the population.

Secondary objectives:

1. To compare the effect of placebo vs oral doxycycline antibiotic in terms of deterioration of illness, symptom severity, and healthcare consultations.
2. To undertake a cost consequence analysis of placebo vs oral doxycycline antibiotic.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 16/10/2024, East Midlands – Nottingham 2 REC (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 207 104 8009; nottingham2.rec@hra.nhs.uk), ref: 24/EM/0205

Study design

Randomized double-blind parallel-group placebo-controlled study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

GP practice

Study type(s)

Efficacy

Participant information sheet**Health condition(s) or problem(s) studied**

Medical condition: Non-complicated lower respiratory tract infection

Medical condition in lay language: non-complicated chest infection

Therapeutic areas: Diseases [C] - Respiratory Tract Diseases [C08]

Interventions

Doxycycline 100mg orally for five days. Two tablets on day 1 and one tablet on days 2-5, OR matched placebo. Participants will be randomised using the ALEA Clinical randomisation tool on a 1:1 ratio.

Intervention Type

Drug

Pharmaceutical study type(s)

Pharmacoeconomic

Phase

Phase III

Drug/device/biological/vaccine name(s)

Doxycycline Capsules BP 100mg [Doxycycline hyclate]

Primary outcome measure

Time until all symptoms (cough, phlegm, shortness of breath, wheeze, blocked or runny nose, chest pain, muscle aches, headaches, disturbed sleep, general feeling of being unwell, fever and interference with normal activities) are rated as "absent" or "mild" (scoring 2 or less on a 0-6 point scale) by patients in their self-reported daily diaries

Secondary outcome measures

1. Deterioration of illness (return to the doctor with a worsening of symptoms, new symptoms or signs, illness requiring hospital admission, or death within four weeks) measured using the self-reported patient diaries, on Days 7, 14, 21 and 28
2. Symptom severity during days 2-4 after the initial consultation (patients tell us that this is the period when their symptoms are worst) measured daily, using the self-reported patient diary

3. Antibiotic consumption over 28 days measured using patient self-reporting in a daily diary
4. Total symptom score over time by a patient measured using self-reporting in a daily diary
5. Personal costs to patients and productivity costs measured using a health economist questionnaire in the patient-reported diary at day 28
6. Health-related quality of life measured using the EuroQol EQ-5D-5L questionnaire on day 0 (day of consent), and then every 7 days until day 28
7. Time until return to usual activities (effect on usual activities rated as 'no problem') measured using the health-related quality of life questionnaire] at baseline, and days 7, 14, 21 and 28

Overall study start date

27/08/2024

Completion date

31/07/2027

Eligibility

Key inclusion criteria

1. Age 65 years and over
2. Presenting in primary care with signs and symptoms suggestive of an uncomplicated LRTI, defined as acute cough (rated moderately severe or worse and lasting for 14 days or less), and at least one of the following signs or symptoms: productive cough, rhonchi on auscultation, temperature $\geq 38^{\circ}\text{C}$, dyspnoea
3. One or more of the following risk factors for complicated illness:
 - 3.1. Age 80 or over
 - 3.2. ≥ 1 unplanned hospital admissions in the previous year
 - 3.3. Type 1 or 2 diabetes, chronic cardiovascular disease, chronic lung disease, chronic kidney disease, chronic liver disease, chronic neuromuscular disease
 - 3.4. Clinical frailty score ≥ 4

Participant type(s)

Patient

Age group

Senior

Lower age limit

65 Years

Sex

Both

Target number of participants

702

Key exclusion criteria

1. Clinical diagnosis of pneumonia
2. A known positive test for a viral respiratory pathogen (e.g. COVID-19 or influenza) during current illness (testing will only occur if part of routine practice)
3. Cough thought to most likely have a non-infective origin (e.g. PE, LVF)

4. Patient needs same-day secondary care assessment or hospital admission
5. Significant impaired immunity, e.g. hematologic malignancy, chronic use of oral steroids (≥ 5 mg prednisolone (or equivalent) per day for 7 days or more), known immunodeficiencies
6. Moderate to severe COPD
7. Hospitalisation in the month before index consultation
8. Antibiotic use for respiratory tract infection in the month before index consultation
9. Tetracycline allergy
10. Patient with bronchiectasis, cystic fibrosis or primary ciliary dyskinesia (not often seen in primary care)
11. Inability to complete the patient diary
12. Taking part in another CTIMP

Date of first enrolment

18/02/2025

Date of final enrolment

14/03/2027

Locations

Countries of recruitment

England

United Kingdom

Wales

Study participating centre

Oaks Healthcare

26-30 London Road
Waterlooville, Hampshire
United Kingdom
PO8 8DL

Study participating centre

Bicester Health Centre

The Health Centre
Coker Close
Bicester
United Kingdom
OX26 6AT

Study participating centre

Hedena Health

207 London Road

Headington
Oxford
United Kingdom
OX3 9JA

Study participating centre

The Boathouse Surgery

Whitchurch Road
Pangbourne
Reading
United Kingdom
RG8 7DP

Study participating centre

Melrose Surgery

73 London Road
Reading
United Kingdom
RG1 5BS

Study participating centre

Marine Lake Medical Practice

Marine Lake Health & Wellbeing Ctr
Orrysdale Road
West Kirby
Wirral
United Kingdom
CH48 5AA

Study participating centre

Vauxhall Health Centre

111-117 Limekiln Lane
Vauxhall
Liverpool
United Kingdom
L5 8XR

Study participating centre

Shifa Surgery

Bangor Street
Blackburn

United Kingdom
BB1 6DY

Study participating centre

Station House Surgery

Station Road
Kendal, Cumbria
United Kingdom
LA9 6SA

Study participating centre

Nettleham Medical Practice

14 Lodge Lane
Nettleham
Lincoln
United Kingdom
LN2 2RS

Study participating centre

Albany House Medical Centre

3 Queen Street
Wellingborough
United Kingdom
NN8 4RW

Study participating centre

Oaklands Health Centre

Huddersfield Road
Holmfirth
United Kingdom
HD9 3TP

Study participating centre

Bartholomew Medical Group

Goole Health Centre
Woodland Avenue
Goole
United Kingdom
DN14 6RU

Study participating centre
James Alexander Family Practice
Bransholme Health Centre
Goodhart Road
Bransholme
Hull
United Kingdom
HU7 4DW

Study participating centre
Preston Hill Surgery
121 Preston Hill
Kenton, Harrow
United Kingdom
HA3 9SN

Study participating centre
The Haven Surgery
The Haven, Burnhope
Durham, County Durham
United Kingdom
DH7 0BD

Study participating centre
West End Medical Centre
Rhoslan Surgery, Conway Road
Colwyn Bay
United Kingdom
LL29 7LS

Study participating centre
Clarence Medical Centre
West Kinmel Street
Rhyl
United Kingdom
LL18 1DA

Study participating centre
Wareham Surgery
Streche Rd

Wareham
United Kingdom
BH20 4PG

Study participating centre

Bay Medical Group

York Bridge Site
5 James Street
Morecambe
United Kingdom
LA4 5TE

Study participating centre

Ashgrove Surgery

Morgan Street
Pontypridd
United Kingdom
CF37 2DR

Sponsor information

Organisation

University of Southampton

Sponsor details

SCTU, Tremona Road
Southampton
England
United Kingdom
SO16 6YD
+44 (0)23 8059 5058
afloat@soton.ac.uk

Sponsor type

University/education

Website

<https://www.southampton.ac.uk/>

ROR

<https://ror.org/01ryk1543>

Funder(s)

Funder type

Government

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

NIHR Health Technology Assessment Programme, HTA

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

1. Peer reviewed scientific journals
2. Conference presentation
3. Other publication
4. The data will be published and available in the public domain. Our PPI colleagues will advise on the report to ensure the language is appropriate and accessible.

Intention to publish date

31/07/2028

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from afloat@soton.ac.uk

IPD sharing plan summary

Available on request